glp1ledger

Alli: The Over-the-Counter Weight-Loss Pill, Its 60 mg Trials, the Liver Review and the 2014 Recall

Alli is orlistat 60 mg, the only FDA-approved weight-loss drug sold without a prescription in the US. Its own trials, the warnings on its Drug Facts label, the FDA's 2010 liver review and the 2014 tampering recall, read 17 November 2026.

Ronald R · Edited by Caroline S · Published 2026-11-17

Illustration: A partially open, unbranded cardboard box and an empty glass on a wooden kitchen counter.
Illustration

Alli is the one weight-loss drug an American adult can buy off a pharmacy shelf. It is orlistat — the same molecule as prescription Xenical — at half the dose, and it has been sold without a prescription since 2007. The record behind it is smaller and shorter than most people assume: its own trials ran 16 to 24 weeks, and the effect they measured is a pound or two beyond diet alone. Its history also includes a nationwide recall that had nothing to do with the drug itself.

This page reads Alli's current Drug Facts label (Haleon US Holdings, effective 18 March 2026), its Drugs@FDA record, the published trials of the 60 mg dose, the FDA's 2010 liver-injury review and the 2014 tampering recall, all on 17 November 2026. The pharmacology of orlistat and the trials of the 120 mg prescription dose are on orlistat (Xenical and Alli); this page is about the product on the shelf.

What Alli is, on the record

Alli
Active ingredient Orlistat 60 mg per capsule
Status Over the counter (non-prescription)
FDA approval 7 February 2007, NDA 021887
Application holder today Haleon US Holdings LLC
Labelled use "Weight loss in overweight adults, 18 years and older, when used along with a reduced-calorie and low-fat diet"
Label's own effect statement 2–3 extra pounds for every 5 lost by diet alone; "most people lost 5-10 pounds over 6 months"

Sources: Alli Drug Facts (openFDA label record a2d3bd73-f3af-4ea5-a57c-66b0004cfe4f); Drugs@FDA via openFDA, NDA 021887. Both read 17 November 2026.

It is the only one. The openFDA Drugs@FDA extract lists two orlistat applications in total: Xenical (NDA 020766, prescription, now held by Cheplapharm) and Alli. No other over-the-counter orlistat product appears. The broader question of whether anything else for weight loss can be bought without a prescription is on is there an over-the-counter GLP-1?.

The labelled schedule, a multivitamin at bedtime and the diet the label pairs it with are the label's own statements. They are reported here, not instructions.

What the 60 mg trials measured

Alli's label compresses its evidence into one sentence. The trials behind the 60 mg dose are published, and they are short:

Trial Who Length Orlistat 60 mg Placebo
Anderson et al. 2006, 20 US centres 391 mildly to moderately overweight adults 16 weeks −3.05 kg −1.90 kg
Smith et al. 2011, multicentre, CT-measured 131 overweight adults (123 analysed) 24 weeks −5.93 kg; visceral fat −15.7% −3.94 kg; visceral fat −9.4%
Shirai et al. 2018, Japan 200 adults with excess visceral fat, no metabolic disease 24 weeks −2.79% of body weight −1.22%
Smith et al. 2012, US Army, Fort Bragg 435 overweight soldiers, 75% men 6 months completers −3.2 kg completers −3.0 kg

Sources: Anderson 2006; Smith 2011; Shirai 2018, funded and largely written by Taisho Pharmaceutical; Smith 2012. All read as abstracts on 17 November 2026; a PubMed search for orlistat 60 mg randomised trials returns eight records, of which these four report weight outcomes for the 60 mg capsule against placebo.

Three things stand out once the trials sit side by side:

  • The difference is about a kilogram or two. In the largest trial, the gap between orlistat and placebo at 16 weeks was 1.15 kg, about 2.5 lb (our arithmetic from the abstract). In the 24-week CT trial it was about 2 kg.
  • Placebo arms lose weight too. Every trial paired both arms with a reduced-calorie diet and education, which is what the label's "for every 5 pounds you lose from diet alone" phrasing describes: the drug adds to diet, it does not replace it.
  • Real-world retention can collapse. In the Army trial only 14% of soldiers completed six months (22 on placebo, 35 on orlistat). Among completers the weight difference was 0.2 kg; the authors' positive finding was about fat mass rather than weight. A trial that keeps one participant in seven tells you little about the other six.

None of the 60 mg trials is longer than about six months. The four-year evidence on orlistat — XENDOS — used the 120 mg prescription dose and is set out on orlistat.

One formulation that is not on the market. A 2018 GSK study found a 27 mg chewable orlistat tablet equivalent to the 60 mg capsule by fecal fat excretion (Johnson & Schwartz 2018). No chewable orlistat appears in the Drugs@FDA extract read on 17 November 2026.

What the Drug Facts label warns

The label's warnings fall into three groups. Each is the label's wording, condensed:

Do not use if you have had an organ transplant (orlistat interferes with anti-rejection medicines), are taking cyclosporine, have been diagnosed with problems absorbing food, are not overweight, or are pregnant or breast-feeding.

Ask a doctor first with a history of gallbladder problems, kidney disease or kidney stones, or pancreatitis — and ask a doctor or pharmacist if taking blood thinners, amiodarone, diabetes medicine, thyroid medicine, seizure medicine, HIV medicine or any other weight-loss product, because doses may need adjusting.

Stop and ask a doctor at signs of liver injury (itching, yellow eyes or skin, dark urine, loss of appetite); at signs of kidney injury (severe back or groin pain, painful urination, blood in the urine, swollen legs or feet, urinating less often); at severe or continuous abdominal pain; or if seizures become more frequent.

A change on the label you can see. openFDA also holds a 2024 copy of the Alli label filed by a repackager (Aphena Pharma Solutions, effective 27 March 2024). Set against Haleon's 2026 label, the older copy asks about "kidney stones" only and carries no kidney-injury stop-use line; the current label adds "kidney disease" and the kidney-injury warning quoted above. The labels themselves do not say when the wording changed. The prescription Xenical label carries oxalate kidney injury among its warnings, set out on orlistat.

The side effects the label expects are bowel changes: "gas with oily spotting, loose stools, more frequent stools that may be hard to control", which it says a low-fat diet makes less likely. The year-one rates measured with the 120 mg dose are in the orlistat page's side-effect table; the 60 mg abstracts read here describe gastrointestinal events as significantly more common on orlistat without printing rates.

The 2010 liver review

In August 2009 the FDA announced it was reviewing reports of liver injury in people using orlistat. On 26 May 2010 it reported the outcome: 13 cases of severe liver injury among an estimated 40 million people who had used Xenical or Alli worldwide — one US report with Alli and 12 reports from outside the US with Xenical. The agency said that "a cause-and-effect relationship of severe liver injury with orlistat use has not been established", approved a revised Xenical label and said it was working with Alli's maker on similar revisions. The stop-use line on today's Alli label is the result.

Source: FDA news release, 26 May 2010, read on PR Newswire on 17 November 2026. The FDA's own safety-communication page for this review returned "not found" when requested on the same day, so the release is cited instead.

The 2014 recall, and why it was not about the drug

In late March 2014 GSK, then Alli's maker, said some Alli packages might contain product that was not authentic Alli, after inquiries from consumers in seven states about bottles holding tablets and capsules of various shapes and colours. By 31 March 2014 it had recalled all Alli from US and Puerto Rico retailers. The drug was not withdrawn for a safety finding about orlistat.

On 25 February 2015 GSK announced Alli's return, saying its review "concluded product tampering occurred after the affected product was shipped to retail outlets", that the FDA's Office of Criminal Investigations was investigating, and that the product would "now feature additional tamper-evident packaging". No published outcome of the criminal investigation was found on 17 November 2026. Fake Alli capsules surfaced again in June 2025, this time through online retailers; Haleon's notice is set beside the FDA's counterfeit-Ozempic seizures on our page on counterfeit weight-loss medicines.

Sources: PharmTech, 31 March 2014; GSK Consumer Healthcare release, Parsippany NJ, 25 February 2015 (reprinted by BioSpace). Both read 17 November 2026.

Beside the GLP-1 figures

No trial compares Alli with a GLP-1 medicine. These are separate trials, each with its own population and length:

Medicine (trial) Population Length Drug Placebo
Alli, orlistat 60 mg (Anderson 2006) Mildly to moderately overweight adults 16 weeks −3.05 kg −1.90 kg
Xenical, orlistat 120 mg (5 pooled trials) Adults with obesity 1 year 13.4 lb 5.8 lb
Semaglutide 2.4 mg (STEP 1) Obesity or overweight with a related condition, no diabetes 68 weeks −15.3 kg (−14.9%) −2.6 kg (−2.4%)

Sources: Anderson 2006; Xenical label section 14.1; STEP 1. The populations, durations and diet programmes differ, so the rows cannot be ranked against one another. Semaglutide 2.4 mg is a prescription injection. Other non-GLP-1 medicines — phentermine, Contrave, Qsymia — are compared on GLP-1 alternatives, and every tablet on the US market is in the register on weight-loss pills.

What we could not read

  • Shelf prices. Pharmacy and retailer pages for Alli did not return readable prices to our request on 17 November 2026, so no price is given. Alli is not in the federal pharmacy acquisition-cost survey that this site uses for prescription drugs.
  • Event rates for the 60 mg dose. The abstracts read here report that gastrointestinal events were more common on orlistat but do not print percentages.
  • Any trial longer than six months of the 60 mg dose.

Alli carries its own warnings panel, and whether it, a prescription medicine or neither suits someone's digestion, other medicines and history is a question for a pharmacist or prescriber.

Sources

  • ALLI (orlistat 60 mg) Drug Facts, Haleon US Holdings LLC, effective 18 March 2026, openFDA set ID a2d3bd73-f3af-4ea5-a57c-66b0004cfe4f; and the repackaged ALLI label, Aphena Pharma Solutions – Tennessee, effective 27 March 2024, set ID 14a75092-f910-53df-e063-6294a90acc66. Read 17 November 2026.
  • Drugs@FDA via openFDA: NDA 021887 (ALLI, over the counter, original approval 7 February 2007, Haleon US Holdings); NDA 020766 (XENICAL, prescription, original approval 23 April 1999, Cheplapharm). Read 17 November 2026.
  • Anderson JW, Schwartz SM, Hauptman J, et al. "Low-dose orlistat effects on body weight of mildly to moderately overweight individuals: a 16 week, double-blind, placebo-controlled trial." Ann Pharmacother 2006;40(10):1717–23, doi:10.1345/aph.1H234, PMID 16940406.
  • Smith SR, Stenlof KS, Greenway FL, et al. "Orlistat 60 mg reduces visceral adipose tissue: a 24-week randomized, placebo-controlled, multicenter trial." Obesity 2011;19(9):1796–803, doi:10.1038/oby.2011.143, PMID 21720429.
  • Shirai K, Fujita T, Tanaka M, et al. Adv Ther 2019;36(1):86–100, doi:10.1007/s12325-018-0835-5, PMID 30535651 (funded by Taisho Pharmaceutical).
  • Smith TJ, Crombie A, Sanders LF, et al. "Efficacy of orlistat 60 mg on weight loss and body fat mass in US Army soldiers." J Acad Nutr Diet 2012;112(4):533–40, doi:10.1016/j.jada.2011.10.006, PMID 22717217.
  • Johnson S, Schwartz SM. "Pharmacologic and pharmacodynamic equivalence of 2 formulations of orlistat." Clin Pharmacol Drug Dev 2018;7(7):773–80, PMID 29659193.
  • U.S. Food and Drug Administration, "FDA: Rare Cases of Liver Injury Reported with Use of Xenical, Alli", news release, 26 May 2010 (PR Newswire).
  • "GSK recalls alli weight-loss products", PharmTech, 31 March 2014; GSK Consumer Healthcare, return-to-market release, 25 February 2015 (BioSpace).
  • Wilding JPH et al. "Once-weekly semaglutide in adults with overweight or obesity." NEJM 2021;384:989–1002, PMID 33567185 (STEP 1).

Frequently asked questions

Is Alli the same as Xenical?

Same drug, half the strength. Both are orlistat. Alli is 60 mg and sold over the counter to overweight adults 18 and older; Xenical is 120 mg, prescription-only and labelled for obesity. Alli's own evidence comes from trials of the 60 mg capsule, the largest of which ran 16 to 24 weeks. Xenical's full trial record, including the four-year XENDOS study, is on our orlistat page.

How much weight can you lose on Alli?

In the largest 60 mg trial, 391 overweight adults lost 3.05 kg on orlistat and 1.90 kg on placebo over 16 weeks, a difference of about 1.2 kg (2.5 lb). In a 24-week trial of 131 adults the figures were 5.93 kg against 3.94 kg. The Alli label summarises it as 2–3 extra pounds for every 5 lost by diet alone, and says most people in its studies lost 5–10 pounds over six months.

Why was Alli taken off the market?

It was not withdrawn for safety. In March 2014 GSK, then its maker, recalled all Alli from US and Puerto Rico shops after consumers in seven states found bottles containing tablets and capsules that were not Alli. The company's review concluded the tampering happened after the product reached retailers. Alli returned on 25 February 2015 with additional tamper-evident packaging.

Does Alli cause liver damage?

Rarely reported, not proven. The FDA's 2010 review found 13 cases of severe liver injury among about 40 million orlistat users worldwide, one of them with Alli in the US, and said cause and effect had not been established. The label now tells users to stop and ask a doctor if they develop itching, yellow eyes or skin, dark urine or loss of appetite.

What are the side effects of Alli?

Mostly bowel changes, because the fat orlistat blocks passes through: the label lists gas with oily spotting, loose stools and more frequent stools that may be hard to control, and says a low-fat diet lowers the chance of them. It also reduces absorption of some vitamins, which is why the label pairs it with a bedtime multivitamin.

Is Alli a GLP-1?

No. Alli works in the gut by blocking fat-digesting enzymes; it does not act on appetite hormones. Every GLP-1 medicine in the US is prescription-only. The labelled one-year effect of orlistat is about 3% of body weight beyond placebo, against 12.4 percentage points for semaglutide 2.4 mg in STEP 1 — separate trials with different populations, not a comparison.